Avant Technologies, Inc. Issues Retraction of September 24, 2025 Press Release
LAS VEGAS, Sept. 24, 2025 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI) (‘Avant’ or the ‘Company’) today announced the retraction of its press release issued on September 24, 2025, regarding a purported Joint Venture and License Agreement with Art-Islets Pte. Ltd. and Austrianova (SGAustria Pte. Ltd.).
The September 24 release contained statements that were issued in error. No binding Joint Venture or License Agreement among Avant Technologies, Art-Islets, and Austrianova has been executed at this time. Accordingly, any descriptions of collaborative activities, technology contributions, or anticipated clinical development milestones contained in that release should not be relied upon.
Avant Technologies regrets the confusion caused by the earlier announcement and is committed to providing only accurate and verified information to its shareholders, partners, and the public.
For future updates and accurate Company information, please visit: https://avanttechnologies.com
Forward-Looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and are subject to risks and uncertainties. Actual results may differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Avant Technologies undertakes no obligation to revise or update such statements.
Contact:
Investor Relations
Avant Technologies, Inc.
Email: [email protected]
Logo – https://mma.prnewswire.com/media/2370694/5528268/Avant_Technologies.jpg
SOURCE Avant Technologies Inc.
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?

Newsrooms &
Influencers

Digital Media
Outlets

Journalists
Opted In
Related news for (AVAI)
- Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
- Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
- Avant Technologies’ Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
- Avant Technologies and JV Partner, Ainnova, Complete Pivotal Meeting with U.S. FDA